Analysis Life Sciences Thank You FDA fiscal year in review: New drug approvals in the wake of the pandemic and legislative reforms
Agency IQ
OCTOBER 6, 2023
AgencyIQ compiled these data using information in approval letters and review packages posted to the Drugs@FDA database. This is a significant jump from any previous year, with the former peak at 15 in FY 2018, followed by several years in the 10-14 range. Amanda Conti, AgencyIQ What kind of biologic products entered the market?
52 
Let's personalize your content